Compare VYGR & QUIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VYGR | QUIK |
|---|---|---|
| Founded | 2013 | 1988 |
| Country | United States | United States |
| Employees | N/A | 51 |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.2M | 211.8M |
| IPO Year | 2015 | 1997 |
| Metric | VYGR | QUIK |
|---|---|---|
| Price | $3.85 | $18.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $16.50 | $11.00 |
| AVG Volume (30 Days) | ★ 488.9K | 424.6K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $10,135,000.00 | ★ $20,112,000.00 |
| Revenue This Year | $34.04 | $75.17 |
| Revenue Next Year | $7.92 | $16.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.65 | $4.80 |
| 52 Week High | $5.55 | $18.88 |
| Indicator | VYGR | QUIK |
|---|---|---|
| Relative Strength Index (RSI) | 47.72 | 78.75 |
| Support Level | $3.72 | $5.67 |
| Resistance Level | $4.31 | N/A |
| Average True Range (ATR) | 0.16 | 1.35 |
| MACD | -0.02 | 0.48 |
| Stochastic Oscillator | 31.91 | 92.32 |
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.
QuickLogic Corp is a fabless semiconductor company developing programmable logic semiconductor technologies, including embedded Field Programmable Gate Array (eFPGA) intellectual property (IP) and specialized FPGA devices. Its product offerings include the eFPGA IP licensing business and associated professional services, as well as a range of FPGA silicon products, including EOS, ArcticLink III, PolarPro 3, PolarPro II, PolarPro, and Eclipse II products, among others. The company's customers come from various markets, including aerospace and defense, industrial and infrastructure systems, data processing and computing platforms, and certain embedded and edge computing applications. Geographically, it generates maximum revenue from North America and the rest from Asia Pacific and Europe.